Dapagliflozin and sacubitril on myocardial microperfusion in patients with post-acute myocardial infarction heart failure and type 2 diabetes

Table 6 Comparison of major adverse cardiovascular events incidence rates between the two groups [n (%)]

Item	Control group (n = 47)	Observation group (n = 51)
Recurrent myocardial infarction	3 (6.38)	1 (1.96)
Heart failure	2 (4.26)	1 (1.96)
Angina pectoris	6 (12.77)	2 (3.92)
Cardiogenic death	1 (2.13)	0 (0.00)
Cumulative MACE incidence	11 (25.53)	4 (7.84)a
F value	0.446
P value	0.979

^aP < 0.05 vs control group.

MACE: Major adverse cardiovascular events.